Lachman Consultants to Offer Insights on Future Transition of Biological Products at the 2019 Parenteral Drug Association (PDA) Annual Meeting

(Westbury, NY – February 2019) Lachman Consultant Services, Inc., a leading provider of expert compliance, regulatory affairs and technical services to life sciences organizations worldwide will be a Bronze Sponsor at the 2019 Annual Meeting of the Parenteral Drug Association (PDA), Booth #308, March 11-13, at the Marriott Marquis San Diego, San Diego, CA. Themed “Solving Manufacturing and Supply Challenges for Current and Future Medicinal Products,” the PDA’s flagship Annual Meeting provides a venue for obtaining the latest information on parenteral processing, manufacturing, supply chain, and quality control.

On the minds of those attending the meeting will be a recent regulation which will transition biological products to be considered as ‘biologics’ rather than ‘new drugs’ under the Federal Food, Drug and Cosmetic Act. The category transition is to be fully complied with by March of 2020. Initially passed in 2010 as part of the Patient Protection and Affordable Care Act, the Biologics Price Competition and Innovations Act codifies the ability of the Food and Drug Administration (FDA) to review and approve biosimilar medicinal products.

“Although March 20, 2020 may seem a long way off, compliance with these new regulations requires a disciplined and well-informed program. A timely approach to pro-actively navigating their complexities is essential,” comments Keith Webber, Ph. D., Vice President, Biotechnology at Lachman. “Our consultants are well-versed and equipped with the knowledge and expertise to guide companies on the pre- and post-approval requirements in order to be prepared for the change and minimize any delay of approval of their applications and supplements.”

Lachman Consultants brings both experience and excellence to its Biopharmaceutical and Biotechnology Consultation Services. Through its dedicated single point of contact approach, multi-disciplinary groups of accomplished FDA and industry experts are assembled from the firm’s Compliance, Regulatory, and Science and Technology Practice Groups. These comprehensive teams are selected and assigned according to each client’s unique set of objectives, needs, and circumstances.

Visitors to the Lachman Consultants booth will have the opportunity to meet with company executives and senior consultants to gain valuable insight about the company’s services for pharmaceutical/biopharmaceutical manufacturing, science, and regulation. In addition to Webber, in attendance will be Fran Zipp, President & CEO, and Linda Evans O’Connor, Vice President & Chief of Staff, as well as several other members of the Lachman Consultants team.